|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Capitalization1 |
87 528 | 94 860 | 132 331 | 131 461 | 181 878 | 203 927 | 203 927 | - |
| Enterprise Value (EV)1 |
102 011 | 109 142 | 144 340 | 143 328 | 206 261 | 227 763 | 224 505 | 219 719 |
| P/E ratio |
29,2x | 44,0x | 97,9x | 41,0x | 1 468x | 51,0x | 28,0x | 21,7x |
| Yield |
4,05% | 3,74% | 2,78% | 2,80% | 2,44% | 2,24% | 2,31% | 2,41% |
| Capitalization / Revenue |
3,90x | 4,29x | 5,43x | 4,94x | 4,86x | 4,59x | 4,38x | 4,00x |
| EV / Revenue |
4,54x | 4,94x | 5,92x | 5,38x | 5,51x | 5,12x | 4,82x | 4,31x |
| EV / EBITDA |
15,2x | 15,3x | 21,6x | 17,2x | 27,2x | 16,4x | 13,9x | 11,4x |
| Enterprise Value (EV) / FCF |
45,3x | 69,3x | 72,5x | 37,3x | 42,3x | 30,5x | 24,1x | 19,5x |
| FCF Yield |
2,21% | 1,44% | 1,38% | 2,68% | 2,36% | 3,28% | 4,15% | 5,14% |
| Price to Book |
5,85x | 7,61x | 10,00x | 8,41x | 4,24x | 5,23x | 4,88x | 4,32x |
| Nbr of stocks (in thousands) |
1 265 982 | 1 266 812 | 1 311 913 | 1 312 660 | 1 549 159 | 1 549 800 | 1 549 800 | - |
| Reference price (USD) |
69,1 | 74,9 | 101 | 100 | 117 | 132 | 132 | 132 |
| Announcement Date |
02/02/2018 | 02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | - | - | - |
1 USD in Million |
|
|
| Income Statement Evolution (Annual data) |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net sales1 |
22 465 | 22 090 | 24 384 | 26 617 | 37 417 | 44 463 | 46 564 | 50 988 |
| EBITDA1 |
6 713 | 7 140 | 6 686 | 8 311 | 7 586 | 13 925 | 16 190 | 19 295 |
| Operating profit (EBIT)1 |
6 855 | 5 672 | 6 436 | 7 340 | 9 928 | 13 718 | 15 304 | 17 888 |
| Operating Margin |
30,5% | 25,7% | 26,4% | 27,6% | 26,5% | 30,9% | 32,9% | 35,1% |
| Pre-Tax Profit (EBT)1 |
2 227 | 1 993 | 1 548 | 3 916 | -265 | 3 633 | 8 566 | 11 780 |
| Net income1 |
3 001 | 2 155 | 1 335 | 3 196 | 112 | 4 027 | 7 770 | 10 046 |
| Net margin |
13,4% | 9,76% | 5,47% | 12,0% | 0,30% | 9,06% | 16,7% | 19,7% |
| EPS2 |
2,37 | 1,70 | 1,03 | 2,44 | 0,08 | 2,58 | 4,69 | 6,06 |
| Free Cash Flow1 |
2 252 | 1 575 | 1 990 | 3 838 | 4 872 | 7 463 | 9 328 | 11 283 |
| FCF margin |
10,0% | 7,13% | 8,16% | 14,4% | 13,0% | 16,8% | 20,0% | 22,1% |
| FCF Conversion |
33,5% | 22,1% | 29,8% | 46,2% | 64,2% | 53,6% | 57,6% | 58,5% |
| Dividend per Share2 |
2,80 | 2,80 | 2,80 | 2,80 | 2,87 | 2,95 | 3,05 | 3,16 |
| Announcement Date |
02/02/2018 | 02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
| Income Statement Evolution (Quarterly data) |
|
|
Fiscal Period: December
|
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
2023 Q3 |
2023 Q4 |
| Net sales1 |
6 275 | 6 578 | 7 410 | 7 320 | 8 220 | 9 866 | 12 011 | 11 390 | 10 771 | 10 982 | 11 325 | 10 654 | 11 174 | 11 679 | 12 340 |
| EBITDA1 |
1 994 | 1 972 | 2 284 | 2 692 | 1 880 | 1 114 | 1 900 | 2 187 | 1 896 | 2 579 | 2 966 | - | - | - | - |
| Operating profit (EBIT)1 |
1 792 | 1 795 | 1 899 | 2 524 | 1 805 | 2 281 | 3 318 | 3 961 | 3 365 | 3 413 | 2 934 | 3 324 | 3 622 | 4 073 | 3 767 |
| Operating Margin |
28,6% | 27,3% | 25,6% | 34,5% | 22,0% | 23,1% | 27,6% | 34,8% | 31,2% | 31,1% | 25,9% | 31,2% | 32,4% | 34,9% | 30,5% |
| Pre-Tax Profit (EBT)1 |
961 | 853 | 1 167 | 1 608 | 764 | -2 001 | -636 | 553 | 247 | 922 | 2 019 | 1 674 | 1 900 | 2 444 | 1 518 |
| Net income1 |
756 | 648 | 1 012 | 1 561 | 550 | -1 652 | -347 | 386 | 360 | 1 640 | 1 866 | 1 338 | 1 519 | 1 954 | 1 170 |
| Net margin |
12,0% | 9,85% | 13,7% | 21,3% | 6,69% | -16,7% | -2,89% | 3,39% | 3,34% | 14,9% | 16,5% | 12,6% | 13,6% | 16,7% | 9,48% |
| EPS2 |
0,58 | 0,49 | 0,78 | 1,19 | 0,42 | -1,10 | -0,22 | 0,25 | 0,23 | 1,05 | 1,04 | - | - | - | - |
| Dividend per Share2 |
0,90 | - | 1,90 | - | 0,90 | - | 1,97 | - | 0,93 | - | 2,46 | - | - | - | 2,95 |
| Announcement Date |
07/30/2020 | 11/05/2020 | 02/11/2021 | 04/30/2021 | 07/29/2021 | 11/12/2021 | 02/10/2022 | 04/29/2022 | 07/29/2022 | 11/10/2022 | - | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Net Debt1 |
14 483 | 14 282 | 12 009 | 11 867 | 24 383 | 23 836 | 20 577 | 15 792 |
| Net Cash position1 |
- | - | - | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
2,16x | 2,00x | 1,80x | 1,43x | 3,21x | 1,71x | 1,27x | 0,82x |
| Free Cash Flow1 |
2 252 | 1 575 | 1 990 | 3 838 | 4 872 | 7 463 | 9 328 | 11 283 |
| ROE (Net Profit / Equities) |
36,4% | 32,0% | 35,6% | 36,7% | 27,5% | 26,2% | 28,2% | 30,1% |
| Shareholders' equity1 |
8 250 | 6 742 | 3 752 | 8 704 | 407 | 15 365 | 27 525 | 33 386 |
| ROA (Net Profit / Asset) |
4,77% | 7,07% | 2,19% | 4,99% | 8,77% | 5,09% | 9,00% | 10,7% |
| Assets1 |
62 940 | 30 480 | 61 015 | 64 053 | 1 277 | 79 181 | 86 372 | 94 274 |
| Book Value Per Share2 |
11,8 | 9,84 | 10,1 | 11,9 | 27,7 | 25,1 | 27,0 | 30,5 |
| Cash Flow per Share2 |
2,82 | 2,07 | 2,28 | 3,66 | 4,18 | 6,52 | 7,73 | 8,97 |
| Capex1 |
1 326 | 1 043 | 979 | 961 | 1 091 | 1 508 | 1 612 | 1 761 |
| Capex / Sales |
5,90% | 4,72% | 4,01% | 3,61% | 2,92% | 3,39% | 3,46% | 3,45% |
| Announcement Date |
02/02/2018 | 02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
|
|
|
Exclusive-Drugmakers to raise prices on at least 350 drugs in U.S. in January |
| Capitalization (GBP) |
164 960 715 193 |
| Capitalization (USD) |
203 927 106 751 |
| Net sales (USD) |
37 417 000 000 |
| Number of employees |
83 100 |
| Sales / Employee (USD) |
450 265 |
| Free-Float |
96,5% |
| Free-Float capitalization (GBP) |
159 118 556 368 |
| Free-Float capitalization (USD) |
196 704 935 430 |
| Avg. Exchange 20 sessions (USD) |
14 808 396 516 |
| Average Daily Capital Traded |
8,98% |
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
Previous period
